

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

March 6th, 2023

**Presentation of data from our pipeline
at the American Association for Cancer Research Annual Meeting 2024**

Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancer, will present new data at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San Diego, California.

Five presentations will be given on Chordia's pipeline of CLK inhibitor CTX-712, CDK12 inhibitor CTX-439, and a GCN2 inhibitor.

Presentation on CTX-712, CLK inhibitor

Abstract No	CT115
Title	A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort
Session No	Poster Section 48
Time	Monday Apr 8, 2024, 1:30 PM - 5:00 PM

Abstract No	CT110
Title	A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts
Session No	Poster Section 48
Time	Monday Apr 8, 2024, 1:30 PM - 5:00 PM

Abstract No	2081
Title	Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials
Session No	Poster Section 29
Time	Monday Apr 8, 2024, 9:00 AM - 12:30 PM

Presentation on CTX-439, CDK12 inhibitor

Abstract No	3301
Title	Translational Research of CDK12/13 Inhibitor, CTX-439, Informing Clinical Trial Strategy
Session No	Poster Section 27
Time	Monday Apr 8, 2024, 1:30 PM - 5:00 PM

Presentation on GCN2 inhibitor

Abstract No	1233
Title	Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma
Session No	Minisymposium
Time	Sunday Apr 7, 2024, 3:00 PM - 5:00 PM

About CTX-712

CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays an important role in cell growth. For more information, please visit: jRCT2080224127 for details on the Japan phase 1 clinical trial and clinicaltrials.gov/ (NCT05732103) for details on the US Phase 1/2 clinical trial of CTX-712.

About Chordia Therapeutics

Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, is developing novel cancer therapies. Chordia's lead asset, CLK inhibitor CTX-712, is currently in Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets vulnerabilities in cancer and could benefit patients with various types of cancer. In addition to CTX-712, Chordia is researching several preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, please contact Mizobe in IR: ir@chorditherapeutics.com